Aradigm Corporation
http://www.aradigm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aradigm Corporation
Spain's Rovi In Line For €3.4bn Windfall With CDMO Sale
The Madrid-headquartered group could see its finances transformed with a sale of its third party manufacturing services which have blossomed through its partnership with Moderna.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
AbbVie Cranks Up Temperature In IBD Market With Celsius Buyout
The drug maker is spending $250m to acquire privately held Celsius and its lead candidate, a monoclonal antibody targeting TREM1 in inflammatory bowel disease.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice